scAAV Rh74-CAG-GFP

Self-complementary adeno-associated virus serotype Rh74 (scAAV Rh74) is a cutting-edge viral vector system that combines the safety advantages of AAV with enhanced transduction efficiency. Unlike traditional single-stranded AAV vectors that require second-strand synthesis, scAAV particles package an inverted repeat genome that rapidly forms double-stranded DNA upon entering the cell. This unique characteristic allows for faster and more robust transgene expression while maintaining the hallmark advantages of AAV: low immunogenicity, stable long-term expression, and the ability to infect both dividing and non-dividing cells. The Rh74 serotype possesses unique tissue tropism advantages, particularly efficient transduction of musculoskeletal tissue, neurons, and various epithelial cells. Its capsid structure exhibits low cross-reactivity with neutralizing antibodies against common AAV serotypes, which is especially important for patients with pre-existing immunity. Furthermore, compared to many traditional serotypes, scAAV Rh74 demonstrates faster nuclear translocation kinetics and higher vector genome retention rates.

The scAAV Rh74 platform has been widely used in gene therapy research and preclinical development. In neuromuscular diseases, it exhibits superior transduction efficiency in skeletal muscle and motor neurons, making it an ideal candidate for treating diseases such as spinal muscular atrophy and Duchenne muscular dystrophy. In neuroscience applications, it can cross the blood-brain barrier at moderate doses, enabling systemic administration for central nervous system disorders. The rapid expression kinetics make scAAV Rh74 particularly valuable in CRISPR-Cas9 gene editing applications, where timely expression of the nuclease is crucial.